Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2004
Business Overview: The Company manufactures pharmaceutical closure systems and drug delivery systems. Operations are divided into Pharmaceutical Systems and Drug Delivery Systems segments. The period includes the impact of a two-for-one stock split completed on September 29, 2004, and ongoing recovery efforts following a January 2003 explosion at the Kinston, NC facility.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 30, 2004 |
3 Months Ended Sept 30, 2003 |
9 Months Ended Sept 30, 2004 |
9 Months Ended Sept 30, 2003 |
|---|---|---|---|---|
| Net Sales | $135,300 | $120,100 | $407,000 | $364,300 |
| Gross Profit | $36,700 | $35,800 | $120,100 | $113,600 |
| Operating Profit | $6,400 | $6,900 | $28,800 | $24,200 |
| Net Income | $4,300 | $4,100 | $19,000 | $14,800 |
| Diluted EPS | $0.14 | $0.14 | $0.62 | $0.51 |
| Cash from Operations (9mo) | $44,800 | $50,300 | ||
| Cash & Equivalents (End Period) | ||||
| Total Debt (Notes + Long-term) | $162,700 | $175,000 | ||
| Working Capital | $111,600 | $97,800 |
Note: Debt figures represent Notes Payable ($300) plus Long-term Debt ($162,400) as of Sept 30, 2004. Prior year debt figures derived from Dec 31, 2003 balance sheet ($8,000 + $167,000).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% in the quarter and 12% year-to-date compared to 2003. Growth was driven by strong demand for Westar-treated components, coated closures, and international sales (Europe/Asia Pacific), partially offset by foreign currency translation impacts.
- Profitability: Operating profit decreased slightly in the quarter ($6.4M vs $6.9M) but increased year-to-date ($28.8M vs $24.2M). The decline in quarterly operating profit was primarily due to $3.1M in additional production and business interruption costs related to the Kinston plant, which were not offset by insurance recoveries in 2004 (unlike 2003).
- Segment Performance: Pharmaceutical Systems operating profit declined $1.8M in the quarter due to Kinston-related costs. Drug Delivery Systems operating losses narrowed to $3.7M from $5.0M due to lower program spending.
- Corporate Costs: Increased to $6.2M in the quarter (from $4.8M) due to $1.4M in stock-based compensation expenses and $0.3M in Kinston-related legal costs.
- Balance Sheet: Cash and equivalents increased to $63.3M from $37.8M at year-end 2003, aided by the receipt of $41.0M in insurance proceeds in February 2004. Total debt decreased as the company repaid borrowings.
Guidance, Outlook, and Risks
- Kinston Facility Recovery: The Kinston plant is operating at approximately 60% capacity. Management expects interim production costs to decrease in early 2005 as the new facility achieves full customer qualification. Full-year 2004 capital spending is projected at $60.0M, with $13.4M related to the Kinston facility.
- Strategic Alternatives: In June 2004, the Company announced plans to explore strategic alternatives for its Drug Delivery Systems segment.
- Tax Legislation: The American Jobs Creation Act of 2004 was signed in October 2004. Management is studying the impact but intends to continue indefinitely reinvesting undistributed foreign earnings, meaning no deferred tax liability has been recorded.
- Stock-Based Compensation: The Company awarded 378,900 performance vesting restricted shares in 2004. Full-year expense is estimated at $4.3M, subject to performance targets.
- Legal and Contingencies: The Company is a defendant in three lawsuits related to the 2003 Kinston explosion. While one suit seeks unspecified damages, the Company believes it has sufficient insurance to cover expected losses. Environmental remediation liabilities are accrued at $2.3M.
- Debt Covenants: The Company is in compliance with its new $125M revolving credit facility. The Leverage Ratio was 26.7% (limit 50%) and Consolidated Net Worth was $259.0M (minimum $198.9M).
Investor Verification Checklist
- Kinston Cost Trajectory: Verify the timeline for the Kinston facility to reach full capacity and the projected reduction in interim production costs in 2005.
- Drug Delivery Segment Strategy: Monitor updates regarding the strategic alternatives being explored for the Drug Delivery Systems segment, which continues to report operating losses.
- Insurance Recovery Finality: Confirm that no further insurance recoveries are expected for business interruption losses, as the settlement was finalized in 2003.
- Stock-Based Compensation Impact: Track the vesting of the 2004 performance restricted shares and the resulting expense recognition, which is variable based on revenue and return on invested capital targets.
- Foreign Currency Exposure: Assess the impact of foreign currency fluctuations on future earnings, given that a significant portion of sales growth was attributed to currency translation.